EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII



Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII



British Journal of Haematology 126(3): 398-404



There have been recent reports of unexpected poor efficacy of a B-domain-deleted recombinant factor VIII (BDD-rFVIII) in haemophiliacs, and inhibitor development in previously treated patients (PTPs) switched to BDD-rFVIII. The results of a 6-month prospective study of 25 PTPs and of a retrospective survey of 94 PTPs, all switched to BDD-rFVIII, were used to evaluate efficacy and inhibitor development. The prospective study showed that 89% of 362 bleeds were controlled by one to two infusions, reproducing the efficacy profiles of other recombinant products (rFVIIIs). One patient, previously treated with plasma-derived FVIII only, developed a high titre inhibitor (30 BU) after 5 days of exposure. The retrospective survey, carried out in the total Italian PTP population switched to BDD-rFVIII, involved 19 PTPs at higher inhibitor risk due to previous exposure of < or = 50 days and 75 PTPs at lower inhibitor risk due to previous exposure of > 50 days. One patient developed an inhibitor: he was a high-risk, severe PTP previously exposed to another rFVIII for 3 days only. Among the entire low-risk population of severe Italian PTPs switched to BDD-rFVIII (25 in the prospective study, 49 in the retrospective cohort) only one developed an inhibitor (1.3%). These data indirectly support the views that BDD-rFVIII is equivalent to other rFVIIIs in term of efficacy and inhibitor development.

(PDF emailed within 0-6 h: $19.90)

Accession: 012025630

Download citation: RISBibTeXText

PMID: 15257713

DOI: 10.1111/j.1365-2141.2004.05058.x



Related references

Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII - clarification of Kogenate inhibitor data. British Journal of Haematology 130(1): 145-6; Author Reply 146-7, 2005

Safety, efficacy and inhibitor development in previously untreated patients treated exclusively with recombinant B-domain deleted F VIII 25 study years. Blood 90(10 SUPPL 1 PART 1): 599A, Nov 15, 1997

Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients. Journal of Thrombosis and Haemostasis 1(11): 2450-2451, 2003

Safety and efficacy of a second generation, B-domain deleted recombinant factor VIII in previously treated patients A four year update. Blood 92(10 SUPPL 1 PART 1-2): 555A, Nov 15, 1998

A prospective surveillance study of inhibitor development in haemophilia A patients following a population switch to a third-generation B-domain-deleted recombinant factor VIII. Haemophilia, 2018

Safety, efficacy and inhibitor development in previously untreated patients treated exclusively with recombinant B domain deleted recombinant FVIII. Blood 94(10 SUPPL 1 PART 1): 234a-235a, Nov 15, 1999

Safety and efficacy of ReFacto, the B domain-deleted recombinant factor VIII , in home therapy of previously treated patients with severe hemophilia A An Italian multicenter trial. Blood 96(11 Part 1): 262a, November 16, 2000

The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 9(1): 38-49, 2003

The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update. Haemophilia 11(3): 292-293, 2005

Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Seminars in Hematology 38(2 Suppl 4): 44-51, 2001

Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia 15(4): 869-880, 2010

Antibody and inhibitor patterns in previously untreated patients treated exclusively with B-domain deleted recombinant factory VIII. Blood 96(11 Part 1): 266a, November 16, 2000

Routine prophylaxis treatment in previously treated patients with B-domain deleted recombinant factor VIII. Blood 94(10 SUPPL 1 PART 1): 235a, Nov 15, 1999

The use of recombinant factor VIII products in previously treated patients with hemophilia A: pharmacokinetics, efficacy, safety, and inhibitor development. Seminars in Thrombosis and Hemostasis 28(3): 241-246, 2002

Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China. Haemophilia 13(4): 351-356, 2007